Skip to content

Study · Systematic review · 2024

5 results

Clinical Pharmacokinetics of Semaglutide: A Systematic Review.

Yang XD, Yang YY

Drug design, development and therapy25 Jun 2024Cited by 69 (Europe PMC)

PMID38952487 (opens in a new tab)PMCIDPMC11215664 (opens in a new tab)DOI10.2147/dddt.s470826 (opens in a new tab)PepBankPUB-38952487
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanSystematic reviewPharmacokinetics

    In human studies, semaglutide had a predictable pharmacokinetic profile with a long half-life that allows once-weekly subcutaneous dosing.

    In plain wordsIn people, semaglutide stays in the body for a long time, so one injection a week can work.

    Peptide
    Semaglutide
    Outcome
    Not applicableHalf-life and dosing interval
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneous and oralAs given in this study (human).

    Source sentences

    Summary
    Semaglutide has a predictable pharmacokinetic profile with a long t1/2 that allows for once-weekly subcutaneous administration.
    1 context sentence
    Summary · context
    The systematic literature search retrieved 17 articles including data on pharmacokinetic profiles after subcutaneously and oral applications of semaglutide, and at least one of the above pharmacokinetic parameter was reported in all included studies.
  2. 02HumanSystematic reviewPharmacokinetics

    In human studies, the AUC and Cmax of oral and subcutaneous semaglutide increased with dose.

    In plain wordsIn people, higher semaglutide doses gave higher levels of the drug in the blood.

    Peptide
    Semaglutide
    Outcome
    IncreaseAUC and Cmax by dose
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneous and oralAs given in this study (human).

    Source sentences

    Summary
    The AUC and Cmax of both oral and subcutaneous semaglutide increased with dose.
    1 context sentence
    Summary · context
    The systematic literature search retrieved 17 articles including data on pharmacokinetic profiles after subcutaneously and oral applications of semaglutide, and at least one of the above pharmacokinetic parameter was reported in all included studies.
  3. 03HumanSystematic reviewPharmacokinetics

    In human studies, food and dosing conditions such as water volume and dosing schedule can affect oral semaglutide exposure.

    In plain wordsIn people, food, water volume and dosing times can change how much oral semaglutide enters the blood.

    Peptide
    Semaglutide
    Outcome
    MixedEffect of food and dosing conditions on oral exposure
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneous and oralAs given in this study (human).

    Source sentences

    Summary
    Food and various dosing conditions including water volume and dosing schedules can affect the oral semaglutide exposure.
    1 context sentence
    Summary · context
    The systematic literature search retrieved 17 articles including data on pharmacokinetic profiles after subcutaneously and oral applications of semaglutide, and at least one of the above pharmacokinetic parameter was reported in all included studies.
  4. 04HumanSystematic reviewPharmacokinetics

    In human studies, semaglutide had limited drug-drug interactions and needed no dose adjustment in upper gastrointestinal disease, renal impairment or hepatic impairment.

    In plain wordsIn people, semaglutide had few drug interactions and no dose change was needed for gut, kidney or liver problems.

    Peptide
    Semaglutide
    Outcome
    No significant changeDrug interactions and organ impairment
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneous and oralAs given in this study (human).

    Source sentences

    Summary
    There are limited drug-drug interactions and no dosing adjustments in patients with upper gastrointestinal disease, renal impairment or hepatic impairment.
    1 context sentence
    Summary · context
    The systematic literature search retrieved 17 articles including data on pharmacokinetic profiles after subcutaneously and oral applications of semaglutide, and at least one of the above pharmacokinetic parameter was reported in all included studies.
  5. 05HumanSystematic reviewPharmacokinetics

    In human studies, body weight may affect semaglutide exposure, but this needs further confirmation.

    In plain wordsIn people, body weight may change semaglutide levels in the blood, but this is not yet confirmed.

    Peptide
    Semaglutide
    Outcome
    Not applicableEffect of body weight on exposure
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneous and oralAs given in this study (human).

    Source sentences

    Summary
    Body weight may affect semaglutide exposure, but further studies are needed to confirm this.
    1 context sentence
    Summary · context
    The systematic literature search retrieved 17 articles including data on pharmacokinetic profiles after subcutaneously and oral applications of semaglutide, and at least one of the above pharmacokinetic parameter was reported in all included studies.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.